Radiofrequency in Knee Osteoarthritis
ConditionAnalgesia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorZagazig University
About this trial
Knee osteoarthritis is one of the most common causes of chronic pain and disability worldwide, particularly in middle-aged and elderly populations. It is characterised by progressive cartilage degeneration, subchondral bone remodelling, and synovial inflammation.
There were many trails to provide pain relief by using systemic opioids or Non steroidal anti inflammatory drugs (with side effects such as peptic ulcer and hepatic, renal impairment)
Eligibility criteria
This trial accepts healthy volunteersQualifiers
American society of anesthesiologist's physical status class I, II- Body mass index (BMI): 18.5 - 29.9 kg/m2- Confirmation of knee OA on radiograph- Chronic knee pain ≥ 3 months.
Disqualifiers
History of clinically significant cardiac, hepatic, renal or neurological disease- Allergy to study medication- Coagulopathy- Infection at injection site
Trial design
Design model
Parallel
Treatments tested in this trial
Laser genicular nerve ablation
Procedure/SurgeryUltrasoud guided Laser genicular nerve ablation for pain relief in knee osteoarthritis
Conventional radiofrequency genicular nerve ablation
Procedure/SurgeryConventional radiofrequency genicular nerve ablation for pain relief in knee osteoarthritis
Treatment groups
50 Participants
are divided into 2 treatment groupsGroup A: Laser genicular nerve ablationActive comparator 1 intervention
Group B: Conventional Radiofrequency genicular nerve ablationActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Visual Analogue scale pain score
To assess pain intensity using Visual Analogue Scale score between laser and radiofrequency group with score 10 indicates worst pain and score 0 indicates no pain.
Time frame
24 hourLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: